Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the three and nine months ended September 30, 1996. Gilead is a biopharmaceutical company focused on research and development, with significant commercialization efforts beginning in 1996 following the FDA approval of VISTIDE (cidofovir injection) for treating cytomegalovirus retinitis in AIDS patients in June 1996.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1996 | Nine Months Ended Sep 30, 1996 | As of Sep 30, 1996 |
|---|---|---|---|
| Total Revenues | $24.7 million | $27.6 million | - |
| Net Income (Loss) | $9.3 million | $(13.7) million | - |
| Net Income (Loss) Per Share | $0.30 | $(0.50) | - |
| Research & Development Expenses | $11.2 million | $31.0 million | - |
| Cash and Cash Equivalents | - | - | $156.0 million |
| Short-term Investments | - | - | $134.3 million |
| Total Current Assets | - | - | $306.6 million |
| Total Current Liabilities | - | - | $16.1 million |
| Accumulated Deficit | - | - | $(126.4) million |
Material Changes vs. Prior Period
- Revenue Surge: Total revenues increased from $1.1 million in Q3 1995 to $24.7 million in Q3 1996. This was driven by $20.3 million in contract revenues from new collaboration agreements and $3.4 million in net product sales of VISTIDE.
- Profitability Shift: The company reported a net income of $9.3 million for Q3 1996, compared to a net loss of $8.4 million in Q3 1995. However, the nine-month period ended Sep 30, 1996, still resulted in a net loss of $13.7 million.
- Expense Growth: Research and development expenses rose 36% year-over-year for the quarter to $11.2 million. Selling, general, and administrative expenses increased 176% to $7.6 million due to the launch of VISTIDE sales and marketing infrastructure.
- Liquidity Expansion: Cash and cash equivalents grew from $27.4 million at year-end 1995 to $156.0 million in Q3 1996, bolstered by a February 1996 public offering and license fees.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur losses for the remainder of 1996 and future quarters due to ongoing R&D, clinical trials, and marketing costs. Future profitability is not assured.
- Collaborations: Significant revenue was recognized from agreements with Pharmacia & Upjohn (P&U) for VISTIDE marketing outside the U.S. and Roche for influenza therapies. Additional milestone payments and royalties are contingent on regulatory approvals and sales.
- Capital Needs: The company anticipates substantial expenses for facility expansion ($3.0 million) and R&D. While current resources are deemed adequate for the foreseeable future, future funding may be required via equity, debt, or partnerships.
- Risks: Key risks include the failure of product candidates in clinical trials, regulatory delays, manufacturing challenges, intense competition, and the bankruptcy of a major wholesaler (FoxMeyer Corporation), which resulted in a $629,000 receivable reserve.
Investor Verification Checklist
- Verify the sustainability of revenue streams given the one-time nature of the $20.3 million in contract revenues from P&U and Roche.
- Monitor the commercial performance and market acceptance of VISTIDE, the company's only approved product.
- Assess the impact of the FoxMeyer Corporation bankruptcy on future receivables and credit risk.
- Track progress on clinical trials for pipeline products to evaluate future revenue potential.
- Review the company's cash burn rate against its $290.3 million in liquid assets to determine runway without additional financing.